German
|
English
|
French
Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "L01EC" (14)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Vemurafenib (L01EC01) 1 products
WHO-DDD
L
IP
CI
PP
Zelboraf 240 mg
56 Tablet(s)
1318.22
1450.05
10 %
Coated tablets: Vemurafenibum 240 mg
Roche Pharma
(Schweiz) AG
A / SL
FB
G
Dabrafenib (L01EC02) 5 products
WHO-DDD
L
IP
CI
Tafinlar 50 mg
28 Capsule(s)
820.18
908.40
10 %
Capsules: Dabrafenibum 50 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
CI
Tafinlar 50 mg
120 Capsule(s)
3515.06
3839.25
10 %
Capsules: Dabrafenibum 50 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
CI
Tafinlar 75 mg
28 Capsule(s)
1230.27
1354.40
10 %
Capsules: Dabrafenibum 75 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
CI
Tafinlar 75 mg
120 Capsule(s)
5272.59
5717.50
10 %
Capsules: Dabrafenibum 75 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
IP
CI
Tafinlar 10 mg
210
k.A.
Tablette zur Herstellung einer Suspension zum Einnehmen: Dabrafenibum 10 mg
Novartis Pharma
Schweiz AG
A
FB
G
Encorafenib (L01EC03) 4 products
WHO-DDD
L
IP
CI
Braftovi 50 mg
28
563.97
629.75
10 %
Capsules: Encorafenibum 50 mg
Pierre Fabre Pharma SA
A / SL
FB
G
L
IP
CI
Braftovi 75 mg
42
1256.61
1383.05
10 %
Capsules: Encorafenibum 75 mg
Pierre Fabre Pharma SA
A / SL
FB
G
L
IP
CI
Braftovi 75 mg
168
5026.44
5464.95
10 %
Capsules: Encorafenibum 75 mg
Pierre Fabre Pharma SA
A / SL
FB
G
IP
CI
Braftovi 50 mg
112
k.A.
Capsules: Encorafenibum 50 mg
Pierre Fabre Pharma SA
A
FB
G
Tovorafenib (L01EC04) 4 products
WHO-DDD
CI
Ojemda 100 mg
16
k.A.
Coated tablets: Tovorafenibum 100 mg
Ipsen Pharma Schweiz
GmbH
A
FB
G
Ojemda 100 mg
20
k.A.
Coated tablets: Tovorafenibum 100 mg
Ipsen Pharma Schweiz
GmbH
A
FB
G
Ojemda 100 mg
24
k.A.
Coated tablets: Tovorafenibum 100 mg
Ipsen Pharma Schweiz
GmbH
A
FB
G
CI
Ojemda 25 mg/ml
k.A.
Pulver zur Herstellung einer Suspension zum Einnehmen: Tovorafenibum 300 mg
Ipsen Pharma Schweiz
GmbH
A
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2026
©ywesee GmbH
Settings
|
Help
|
Login
|
Contact
|
Home
